10-Q Filing

Astrana Health, Inc. CIK: 1083446 Q1 2017

Filing Information

Form Type	10-Q
Accession Number	`0001144204-17-043172`
Period End Date	20170630
Filing Date	20170814
Fiscal Year	2017
Fiscal Period	Q1
XBRL Instance	ameh-20170630.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 72 Income Statement 34 Cash Flow Statement 58

Balance Sheet 72 line items

Line Item	Tag	Value	Unit	Period
Accounts receivable, net of allowance for doubtful accounts	`AllowanceForDoubtfulAccountsReceivableCurrent`	$475.08K	USD	Point-in-time
Accounts receivable, net of allowance for doubtful accounts	`AllowanceForDoubtfulAccountsReceivableCurrent`	$461.65K	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$31.21M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$9.27M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$6.51M	USD	Point-in-time
Debt Issuance Costs, Current, Net	`DeferredFinanceCostsCurrentNet`	$107.33K	USD	Point-in-time
Debt Issuance Costs, Current, Net	`DeferredFinanceCostsCurrentNet`	$161.00K	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$8.66M	USD	Point-in-time
Accounts receivable, net of allowance for doubtful accounts of $461,650 and $475,080, respectively	`AccountsReceivableNetCurrent`	$5.42M	USD	Point-in-time
Accounts receivable, net of allowance for doubtful accounts of $461,650 and $475,080, respectively	`AccountsReceivableNetCurrent`	$5.51M	USD	Point-in-time
Other receivables	`AccountsAndOtherReceivablesNetCurrent`	$464.08K	USD	Point-in-time
Other receivables	`AccountsAndOtherReceivablesNetCurrent`	$806.15K	USD	Point-in-time
Due from affiliates	`DueFromAffiliateCurrent`	-	USD	Point-in-time
Due from affiliates	`DueFromAffiliateCurrent`	$18.31K	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$282.73K	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$269.17K	USD	Point-in-time
Total current assets	`AssetsCurrent`	$14.92M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$37.72M	USD	Point-in-time
Common Stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$1.21M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$1.17M	USD	Point-in-time
Common Stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common Stock, shares authorized	`CommonStockSharesAuthorized`	100.00M	shares	Point-in-time
Restricted cash	`RestrictedCashAndInvestmentsCurrent`	$765.06K	USD	Point-in-time
Restricted cash	`RestrictedCashAndInvestmentsCurrent`	$745.12K	USD	Point-in-time
Common Stock, shares authorized	`CommonStockSharesAuthorized`	100.00M	shares	Point-in-time
Common Stock, shares issued	`CommonStockSharesIssued`	6.03M	shares	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$1.82M	USD	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$1.90M	USD	Point-in-time
Common Stock, shares issued	`CommonStockSharesIssued`	6.03M	shares	Point-in-time
Goodwill	`Goodwill`	$1.62M	USD	Point-in-time
Common Stock, shares outstanding	`CommonStockSharesOutstanding`	6.03M	shares	Point-in-time
Goodwill	`Goodwill`	$1.62M	USD	Point-in-time
Common Stock, shares outstanding	`CommonStockSharesOutstanding`	6.03M	shares	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$225.36K	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$221.98K	USD	Point-in-time
TOTAL ASSETS	`Assets`	$20.64M	USD	Point-in-time
TOTAL ASSETS	`Assets`	$43.30M	USD	Point-in-time
Accounts payable and accrued liabilities	`AccountsPayableAndAccruedLiabilitiesCurrent`	$7.88M	USD	Point-in-time
Accounts payable and accrued liabilities	`AccountsPayableAndAccruedLiabilitiesCurrent`	$16.21M	USD	Point-in-time
Medical liabilities	`MedicalLiabilitiesCurrent`	$19.72M	USD	Point-in-time
Medical liabilities	`MedicalLiabilitiesCurrent`	$1.77M	USD	Point-in-time
Convertible note payable, net of debt issuance cost of $107,333 and $161,000, respectively	`ConvertibleNotesPayableCurrent`	$4.83M	USD	Point-in-time
Convertible note payable, net of debt issuance cost of $107,333 and $161,000, respectively	`ConvertibleNotesPayableCurrent`	$4.88M	USD	Point-in-time
Lines of credit	`LinesOfCreditCurrent`	$62.50K	USD	Point-in-time
Lines of credit	`LinesOfCreditCurrent`	$25.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$14.54M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$40.84M	USD	Point-in-time
Note payable - related party	`NotesPayableRelatedPartiesNoncurrent`	$5.00M	USD	Point-in-time
Note payable - related party	`NotesPayableRelatedPartiesNoncurrent`	$5.00M	USD	Point-in-time
Deferred rent liability	`DeferredRentCreditNoncurrent`	$747.42K	USD	Point-in-time
Deferred rent liability	`DeferredRentCreditNoncurrent`	$715.46K	USD	Point-in-time
Deferred tax liability	`DeferredTaxLiabilities`	$83.67K	USD	Point-in-time
Deferred tax liability	`DeferredTaxLiabilities`	$83.67K	USD	Point-in-time
TOTAL LIABILITIES	`Liabilities`	$46.64M	USD	Point-in-time
TOTAL LIABILITIES	`Liabilities`	$20.37M	USD	Point-in-time
COMMITMENTS AND CONTINGENCIES (see Note 8)	`CommitmentsAndContingencies`	-	USD	Point-in-time
COMMITMENTS AND CONTINGENCIES (see Note 8)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Common stock, par value $0.001; 100,000,000 shares authorized, 6,033,518 shares issued and outstanding	`CommonStockValue`	$6.03K	USD	Point-in-time
Common stock, par value $0.001; 100,000,000 shares authorized, 6,033,518 shares issued and outstanding	`CommonStockValue`	$6.03K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$26.56M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$26.33M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-37.65M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-41.27M	USD	Point-in-time
Stockholders deficit attributable to Apollo Medical Holdings, Inc.	`StockholdersEquity`	$-3.74M	USD	Point-in-time
Stockholders deficit attributable to Apollo Medical Holdings, Inc.	`StockholdersEquity`	$-353.88K	USD	Point-in-time
Non-controlling interest	`MinorityInterest`	$403.00K	USD	Point-in-time
Non-controlling interest	`MinorityInterest`	$624.25K	USD	Point-in-time
Total stockholders (deficit) equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$270.37K	USD	Point-in-time
Total stockholders (deficit) equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$-3.34M	USD	Point-in-time
TOTAL LIABILITIES AND STOCKHOLDERS (DEFICIT) EQUITY	`LiabilitiesAndStockholdersEquity`	$20.64M	USD	Point-in-time
TOTAL LIABILITIES AND STOCKHOLDERS (DEFICIT) EQUITY	`LiabilitiesAndStockholdersEquity`	$43.30M	USD	Point-in-time

Income Statement 34 line items

Line Item	Tag	Value	Unit	Period
Net revenues	`Revenues`	$12.37M	USD	1 Quarter
Net revenues	`Revenues`	$41.58M	USD	1 Quarter
Cost of services	`CostOfServices`	$10.13M	USD	1 Quarter
Cost of services	`CostOfServices`	$40.24M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$3.84M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$4.89M	USD	1 Quarter
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$164.66K	USD	1 Quarter
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$155.27K	USD	1 Quarter
Total costs and expenses	`OperatingExpenses`	$14.13M	USD	1 Quarter
Total costs and expenses	`OperatingExpenses`	$45.28M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-3.71M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-1.76M	USD	1 Quarter
Interest expense	`InterestExpense`	$192.99K	USD	1 Quarter
Interest expense	`InterestExpense`	$2.66K	USD	1 Quarter
Gain on change in fair value of warrant liability	`GainLossOnDerivativeInstrumentsNetPretax`	$822.22K	USD	1 Quarter
Gain on change in fair value of warrant liability	`GainLossOnDerivativeInstrumentsNetPretax`	-	USD	1 Quarter
Other income	`OtherNonoperatingIncomeExpense`	$38.66K	USD	1 Quarter
Other income	`OtherNonoperatingIncomeExpense`	$1.97K	USD	1 Quarter
Total other (expense) income, net	`NonoperatingIncomeExpense`	$-154.33K	USD	1 Quarter
Total other (expense) income, net	`NonoperatingIncomeExpense`	$821.53K	USD	1 Quarter
Loss before benefit from income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-3.86M	USD	1 Quarter
Loss before benefit from income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-940.93K	USD	1 Quarter
Benefit from income taxes	`IncomeTaxExpenseBenefit`	$-29.89K	USD	1 Quarter
Benefit from income taxes	`IncomeTaxExpenseBenefit`	$-41.55K	USD	1 Quarter
Net loss	`ProfitLoss`	$-899.38K	USD	1 Quarter
Net loss	`ProfitLoss`	$-3.83M	USD	1 Quarter
Net loss (income) attributable to non-controlling interest	`NetIncomeLossAttributableToNoncontrollingInterest`	$-221.24K	USD	1 Quarter
Net loss (income) attributable to non-controlling interest	`NetIncomeLossAttributableToNoncontrollingInterest`	$415.88K	USD	1 Quarter
Net loss attributable to Apollo Medical Holdings, Inc.	`NetIncomeLoss`	$-1.32M	USD	1 Quarter
Net loss attributable to Apollo Medical Holdings, Inc.	`NetIncomeLoss`	$-3.61M	USD	1 Quarter
Basic and diluted	`EarningsPerShareBasicAndDiluted`	$-0.22	USD	1 Quarter
Basic and diluted	`EarningsPerShareBasicAndDiluted`	$-0.60	USD	1 Quarter
Basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	5.91M	shares	1 Quarter
Basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	6.03M	shares	1 Quarter

Cash Flow Statement 58 line items

Line Item	Tag	Value	Unit	Period
Net loss	`ProfitLoss`	$-899.38K	USD	1 Quarter
Net loss	`ProfitLoss`	$-3.83M	USD	1 Quarter
Provision for doubtful accounts, net of recoveries	`ProvisionForDoubtfulAccounts`	$6.64K	USD	1 Quarter
Provision for doubtful accounts, net of recoveries	`ProvisionForDoubtfulAccounts`	$167.50K	USD	1 Quarter
Depreciation and amortization expense	`DepreciationDepletionAndAmortization`	$164.66K	USD	1 Quarter
Depreciation and amortization expense	`DepreciationDepletionAndAmortization`	$155.27K	USD	1 Quarter
Stock-based compensation expense	`AllocatedShareBasedCompensationExpense`	$247.72K	USD	1 Quarter
Stock-based compensation expense	`AllocatedShareBasedCompensationExpense`	$223.57K	USD	1 Quarter
Amortization of deferred financing costs	`AdjustmentForAmortization`	$53.67K	USD	1 Quarter
Amortization of deferred financing costs	`AdjustmentForAmortization`	$37.93K	USD	1 Quarter
Change in fair value of warrant liability	`GainLossOnDerivativeInstrumentsNetPretax`	$822.22K	USD	1 Quarter
Change in fair value of warrant liability	`GainLossOnDerivativeInstrumentsNetPretax`	-	USD	1 Quarter
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$774.09K	USD	1 Quarter
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$-76.21K	USD	1 Quarter
Other receivables	`IncreaseDecreaseInOtherReceivables`	$342.06K	USD	1 Quarter
Other receivables	`IncreaseDecreaseInOtherReceivables`	$-265.98K	USD	1 Quarter
Due from affiliates	`IncreaseDecreaseDueFromAffiliates`	$-453.00	USD	1 Quarter
Due from affiliates	`IncreaseDecreaseDueFromAffiliates`	$-18.31K	USD	1 Quarter
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets`	$13.56K	USD	1 Quarter
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets`	$215.18K	USD	1 Quarter
Restricted cash	`IncreaseDecreaseInRestrictedCashForOperatingActivities`	$-19.94K	USD	1 Quarter
Restricted cash	`IncreaseDecreaseInRestrictedCashForOperatingActivities`	-	USD	1 Quarter
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$-2.76K	USD	1 Quarter
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$-3.38K	USD	1 Quarter
Accounts payable and accrued liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$-317.45K	USD	1 Quarter
Accounts payable and accrued liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$8.33M	USD	1 Quarter
Deferred rent liability	`IncreaseDecreaseInOtherDeferredLiability`	$33.58K	USD	1 Quarter
Deferred rent liability	`IncreaseDecreaseInOtherDeferredLiability`	$-31.96K	USD	1 Quarter
Medical liabilities	`IncreaseDecreaseInMedicalLiabilities`	$-158.67K	USD	1 Quarter
Medical liabilities	`IncreaseDecreaseInMedicalLiabilities`	$17.95M	USD	1 Quarter
Net cash provided by (used in) operating activities	`NetCashProvidedByUsedInOperatingActivitiesContinuingOperations`	$-2.27M	USD	1 Quarter
Net cash provided by (used in) operating activities	`NetCashProvidedByUsedInOperatingActivitiesContinuingOperations`	$22.62M	USD	1 Quarter
Property and equipment acquired	`PaymentsToAcquirePropertyPlantAndEquipment`	$36.08K	USD	1 Quarter
Property and equipment acquired	`PaymentsToAcquirePropertyPlantAndEquipment`	$163.51K	USD	1 Quarter
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivitiesContinuingOperations`	$-163.51K	USD	1 Quarter
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivitiesContinuingOperations`	$-36.08K	USD	1 Quarter
Principal payments on lines of credit	`RepaymentsOfLinesOfCredit`	$37.50K	USD	1 Quarter
Principal payments on lines of credit	`RepaymentsOfLinesOfCredit`	$12.50K	USD	1 Quarter
Distributions to non-controlling interest shareholder	`PaymentsToMinorityShareholders`	-	USD	1 Quarter
Distributions to non-controlling interest shareholder	`PaymentsToMinorityShareholders`	$450.00K	USD	1 Quarter
Proceeds from the exercise of warrants	`ProceedsFromWarrantExercises`	-	USD	1 Quarter
Proceeds from the exercise of warrants	`ProceedsFromWarrantExercises`	$132.00K	USD	1 Quarter
Net cash used in financing activities	`NetCashProvidedByUsedInFinancingActivitiesContinuingOperations`	$-37.50K	USD	1 Quarter
Net cash used in financing activities	`NetCashProvidedByUsedInFinancingActivitiesContinuingOperations`	$-330.50K	USD	1 Quarter
Net increase (decrease) in cash and cash equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$22.54M	USD	1 Quarter
Net increase (decrease) in cash and cash equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$-2.76M	USD	1 Quarter
Cash and cash equivalents, beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$31.21M	USD	Point-in-time
Cash and cash equivalents, beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$9.27M	USD	Point-in-time
Cash and cash equivalents, beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$6.51M	USD	Point-in-time
Cash and cash equivalents, beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$8.66M	USD	Point-in-time
Cash and cash equivalents, end of period	`CashAndCashEquivalentsAtCarryingValue`	$31.21M	USD	Point-in-time
Cash and cash equivalents, end of period	`CashAndCashEquivalentsAtCarryingValue`	$9.27M	USD	Point-in-time
Cash and cash equivalents, end of period	`CashAndCashEquivalentsAtCarryingValue`	$6.51M	USD	Point-in-time
Cash and cash equivalents, end of period	`CashAndCashEquivalentsAtCarryingValue`	$8.66M	USD	Point-in-time
Interest paid	`InterestPaid`	$7.14K	USD	1 Quarter
Interest paid	`InterestPaid`	$584.00	USD	1 Quarter
Income taxes paid	`IncomeTaxesPaid`	$17.59K	USD	1 Quarter
Income taxes paid	`IncomeTaxesPaid`	$16.40K	USD	1 Quarter

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.